News & Events
Global Genes - Crinetics Raises $100 Million to Advance Rare Endocrine Disease Pipeline
April 15, 2020 — Crinetics has raised $100 million via public offering of 7. 2 million shares of its stock to fund research for the treatment of rare diseases such as acromegaly, Cushing's disease, congenital hyperinsulinism, and congenital adrenal hyperplasia. Read the full article on Global Genes - Allies in Rare Disease.
READ MORECrinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Crinetics intends to use the net proceeds from the proposed offering to fund the development of paltusotine - for the treatment of acromegaly and neuroendocrine tumors (NETs) - and its other research and development programs, and for working capital and general corporate purposes.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
READ MORECrinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
Crinetics (CRNX) announces that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Crinetics intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Crinetics.
READ MORECrinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
SAN DIEGO, April 06, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported interim results from the ongoing ACROBAT Edge Phase 2 trial. Results as of a February 23, 2020 data cutoff showed that acromegaly patients switching from injectable depot therapy to once daily oral paltusotine (formerly CRN00808) maintained IGF-1 levels previously achieved with commercially available depot injections of somatostatin receptor ligands (SRLs).
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced financial results for the fourth quarter and year ended December 31, 2019 and provided a corporate update.
READ MORECrinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
